10 Best Immunology Stocks To Buy Now

6. GSK plc (NYSE:GSK)

Number of Hedge Fund Holders: 38

GSK plc (NYSE:GSK) specializes in pharmaceuticals, vaccines, and consumer health products, with a strong focus on immunology. Its specialty medicines division targets complex diseases like lupus, asthma, and COPD, using advanced technologies to develop innovative treatments.

GSK plc (NYSE:GSK) has made immunology a core therapeutic focus alongside infectious diseases, HIV, and oncology, investing £6.2 billion in R&D in 2023 to strengthen its pipeline, solidifying its position among the best immunology stocks. The company is actively developing several immunology candidates, including CMG1A46, a dual CD19/CD20-targeted T cell engager for lupus, and GSK4527363, a B-cell modulator for systemic lupus erythematosus. Other notable developments include depemokimab, an anti-IL5 antibody in Phase III trials for asthma, and camlipixant, a P2X3 receptor antagonist for refractory chronic cough.

For fiscal Q4 2024, GSK plc (NYSE:GSK) released impressive financial results that showed a robust increase in all important parameters. In 2024, its core operating profit increased by 13% while its sales increased by 8% to nearly £31 billion. Core profits per share (EPS) increased by 12% as well.

GSK plc (NYSE:GSK)’s Specialty Medicines business saw a 19% increase in sales, which was credited with this success. Its oncology revenues almost doubled to over £1.4 billion in 2024, while its HIV sales increased by 13%. With five new product approvals expected in 2025 and 11 successful phase III studies reported in 2024, the company is steadily bolstering its pipeline. These include depemokimab for severe asthma and Blenrep for multiple myeloma.